SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 139 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $428,195 | -39.1% | 29,490 | -12.2% | 0.20% | -38.5% |
| Q2 2023 | $702,746 | +30.0% | 33,576 | +31.1% | 0.32% | -26.8% |
| Q1 2023 | $540,756 | +13.9% | 25,604 | +37.2% | 0.44% | +56.0% |
| Q4 2022 | $474,922 | -46.8% | 18,661 | -49.7% | 0.28% | -44.6% |
| Q3 2022 | $892,000 | +6.3% | 37,104 | -3.2% | 0.51% | -23.8% |
| Q4 2021 | $839,000 | -3.8% | 38,347 | -15.9% | 0.67% | +15.8% |
| Q3 2021 | $872,000 | +6.2% | 45,584 | -4.7% | 0.58% | -0.9% |
| Q2 2021 | $821,000 | +5.4% | 47,814 | +37.1% | 0.58% | +0.5% |
| Q1 2021 | $779,000 | – | 34,873 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |